$AUTL News

Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026

All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy

Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026

Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026

AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for Systemic Lupus Erythematosus and Lupus Nephritis

Autolus Therapeutics plc 2026 Q2 - Results - Earnings Call Presentation

Autolus Therapeutics Q2 Earnings Call Highlights

Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est

Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors

Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150M

Autolus Therapeutics: Navigating A Bumpy 2026

Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)